公开(公告)号：EP2668948A1

公开(公告)日：2013-12-04

申请号：EP12004188.4

申请日：2012-05-31

申请人： G. Pohl-Boskamp GmbH & Co. KG

发明人： Gorath, Dr. Michaela

IPC分类号： A61K31/21 ,  A61K31/34 ,  A61K9/20 ,  A61P9/00

CPC分类号： A61K31/34 ,  A61K9/006 ,  A61K9/145 ,  A61K31/21

摘要： The present invention inter alia relates to a method of treating or preventing an arterial insufficiency, wherein an NO donor is administered in an intermitting manner to a subject in an amount effective for the induction of arteriogenesis, and wherein the NO donor is a solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight% glyceryl trinitrate (GTN), at least one diluent, one carrier material, and at least one substance that reduces the volatility of GTN, whereby this substance is a non-volatile ester stabilizer whose melting point is not higher than 60 °C.

摘要翻译： 本发明尤其涉及一种治疗或预​​防动脉功能不全的方法，其中以有效诱导动脉生成的量以间隔方式向患者施用NO供体，其中NO供体是固体药物制剂 活性物质三硝酸甘油酯用于肠粘膜或口服给药，其特征在于其含有0.05至2重量％的三硝酸甘油酯（GTN），至少一种稀释剂，一种载体材料和至少一种降低GTN挥发性的物质，由此 该物质是熔点不高于60℃的非挥发性酯稳定剂。

公开(公告)号：EP2575766A4

公开(公告)日：2013-11-20

申请号：EP11789347

申请日：2011-06-01

申请人： APOSENSE LTD

发明人： ZIV ILAN ,  GRIMBERG HAGIT

IPC分类号： A61K9/127 ,  A61K31/21 ,  A61K31/33 ,  C07D491/22

CPC分类号： C07D491/22 ,  C07D239/10 ,  C07D403/04 ,  C07H19/06

摘要： Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.

公开(公告)号：EP2640687A1

公开(公告)日：2013-09-25

申请号：EP11793573.4

申请日：2011-11-15

申请人： Eli Lilly and Company

发明人： DRESSMAN, Bruce Anthony ,  CHAPPELL, Mark Donald ,  FIVUSH, Adam Michael ,  MITCH, Charles Howard ,  ORNSTEIN, Paul Leslie ,  TROMICZAK, Eric George ,  VETMAN, Tatiana Natali

IPC分类号： C07C229/50 ,  A61P25/24 ,  A61K31/21

CPC分类号： C07D277/36 ,  A61K31/135 ,  A61K31/138 ,  A61K31/196 ,  A61K31/216 ,  A61K31/265 ,  A61K31/27 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/426 ,  A61K45/06 ,  C07C62/34 ,  C07C69/757 ,  C07C69/96 ,  C07C229/50 ,  C07C233/52 ,  C07C235/14 ,  C07C271/24 ,  C07C2601/02 ,  C07C2602/18 ,  C07D235/00 ,  C07D249/12 ,  A61K2300/00

摘要： A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.

摘要翻译： 描述了下式的mGlu2 / 3受体拮抗剂：其用途及其制备方法。

公开(公告)号：EP2616061A2

公开(公告)日：2013-07-24

申请号：EP11825840.9

申请日：2011-09-14

申请人： Brassica Protection Products LLC

发明人： TALALAY, Paul ,  FAHEY, Jed ,  TALALAY, Antony

IPC分类号： A61K31/21 ,  A61K31/70 ,  A61K31/10

CPC分类号： A61K38/47 ,  A23L29/06 ,  A23L33/17 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/127 ,  A61K31/26 ,  A61K31/7028 ,  C12Y302/01147

摘要： The application relates to topical formulations comprising a phase II enzyme inducer precursor and an activating agent. Methods for producing and using the topical formulations are also provided.

公开(公告)号：EP2056813B1

公开(公告)日：2013-07-10

申请号：EP07788428.6

申请日：2007-08-15

申请人： AMDERMA PHARMACEUTICALS, LLC

发明人： CUEVAS SÁNCHEZ, Pedro ,  GIMÉNEZ GALLEGO, Guillermo ,  SÁENZ DE TEJADA GORMAN, Iñigo ,  ANGULO FRUTOS, Javier ,  VALVERDE LÓPEZ, Serafín ,  ROMERO GARRIDO, Antonio ,  LOZANO PUERTO, Rosa María

IPC分类号： A61K31/185 ,  A61K31/192 ,  A61K31/21 ,  A61K31/216 ,  A61K31/255 ,  A61K31/60 ,  A61P17/00 ,  A61K45/06 ,  A61K31/222

CPC分类号： A61K31/255 ,  A61K9/0014 ,  A61K31/095 ,  A61K31/10 ,  A61K31/185 ,  A61K31/192 ,  A61K31/216 ,  A61K31/222 ,  A61K31/225 ,  A61K31/235 ,  A61K45/06 ,  C07C57/44 ,  C07C59/68 ,  C07C65/03 ,  C07C65/19 ,  C07C69/017 ,  C07C69/84 ,  C07C309/24 ,  C07C309/42 ,  C07C309/68 ,  C07C309/75 ,  A61K2300/00

摘要： The present invention refers to the use of a compound of Formula (I") or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of cancer of an organ.

公开(公告)号：EP2582368A1

公开(公告)日：2013-04-24

申请号：EP11726386.3

申请日：2011-06-10

申请人： Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

发明人： GRILLI, Mariagrazia ,  CANONICO, Pier Luigi ,  KOVERECH, Aleardo

IPC分类号： A61K31/21 ,  A61P25/16 ,  A61P25/28

CPC分类号： A61K31/225 ,  A61K31/205 ,  A61K31/21

摘要： The invention, described herein, is directed to the use of acetyl. L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in winch said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.

摘要翻译： 本文所述的本发明涉及乙酰基的用途。 左旋肉碱或丙酰基左旋肉碱或其盐，用于制备用于增加神经组织中神经发生的药物; 在绞车中，增加的神经发生可用于预防由于老化或遗传倾向引起的中枢神经系统疾病。

公开(公告)号：EP2490711A1

公开(公告)日：2012-08-29

申请号：EP10824316.3

申请日：2010-10-22

申请人： Propanc Pty Ltd

发明人： KENYON, Julian, Norman ,  CLAYTON, Paul, Rodney ,  TOSH, David ,  FELQUER, Fernando ,  BRANDT, Ralf

IPC分类号： A61K38/47 ,  A61K38/48 ,  A61K38/54 ,  A61K31/095 ,  A61K31/21 ,  A61P35/00

CPC分类号： A61K33/04 ,  A61K31/095 ,  A61K31/21 ,  A61K38/47 ,  A61K38/4826 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumour cell to enhance cell-to-cell adhesion of tumour cells, effect proteolysis of tumour cells, or induce tumour cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumour cells.

公开(公告)号：EP2410843A4

公开(公告)日：2012-08-08

申请号：EP10756872

申请日：2010-03-25

申请人： PRESIDIO PHARMACEUTICALS INC

发明人： LI LEPING ,  ZHONG MIN

IPC分类号： A01N37/00 ,  A61K31/21

CPC分类号： C07D405/14 ,  C07D413/14 ,  C07D417/14

公开(公告)号：EP2408444A2

公开(公告)日：2012-01-25

申请号：EP10754130.2

申请日：2010-03-18

申请人： Fate Therapeutics, Inc.

发明人： MENDLEIN, John, D. ,  FAROUZ, Francine, S. ,  THIES, R., Scott ,  SHOEMAKER, Daniel

IPC分类号： A61K31/21 ,  A61K31/35 ,  A61K38/16 ,  A61K31/557 ,  A61P7/00

CPC分类号： A61K31/21 ,  A61K31/35 ,  A61K31/557 ,  A61K38/164 ,  A61K38/2271 ,  Y02A50/471 ,  A61K2300/00

摘要： Provided are improved pharmaceutical compositions that comprise ligands or agonists to prostaglandin EP receptors, and/or cyclic AMP enhancers, and suitable organic solvents that are substantially free of methyl acetate, the compositions being provided for storage and/or use in an endotoxin-free vessel, such as a tube or PE bag. The compositions are suitable for in vitro, ex vivo, and in vivo use, and in particular for ex vivo therapeutic use, such as in hematopoietic stem cell transplants. Also provided are methods of using the compositions in ex vivo therapeutic applications, and methods of preparing the compositions. Kits with instructions on use are also provided.

公开(公告)号：EP2395834A1

公开(公告)日：2011-12-21

申请号：EP10741692.7

申请日：2010-02-11

申请人： Hope Medical Enterprise, Inc. D.b.a. Hope Pharmaceuticals

发明人： SHERMAN, Craig ,  LEPINE, Anthony, James ,  SMITH, Catherine, Marie ,  WIRTZ, Kevin, Robert ,  SCHULZE, Erich

IPC分类号： A01N37/00 ,  A61K31/21

CPC分类号： A61K33/00 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/17 ,  A61K31/4418 ,  A61K31/4709 ,  A61K31/519 ,  A61P9/00 ,  A61P11/00 ,  A61P17/00 ,  A61P43/00 ,  C01B21/50 ,  Y02A50/411 ,  Y10T436/204998

摘要： Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.